IP Library Granted Patent US 9,701,713
Granted Patent B2
US 9,701,713 · App. 14/008,221 · Granted Jul 11, 2017

Compositions and methods for introduction of macromolecules into cells

Inventors: Jonathan Mark Petrash (Englewood, CO); Niklaus Mueller (Denver, CO)
Assignee: The Regents of the University of Colorado, a body corporate
C07K7/08A61K47/48238A61K47/48315C07K14/005C07K14/47A61K38/00C07K2319/10C07K2319/35C12N2710/16622
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,701,713
App. No.
14/008,221
Granted
Jul 11, 2017
Kind
B2
Abstract

Disclosed are novel compositions and methods for introduction of macromolecules and nanoparticles into living cells. The invention includes a polypeptide sequence which when fused to a macromolecule or nanoparticle enhances its introduction into the cell.

Claims (23)

1. A composition comprising:

a) a peptide comprising an amino acid sequence that is at least 80% identical to SEQ ID NO:1 (GSRVQIRCRFRNSTR), and

b) a therapeutic protein or a heat shock protein or a crystallin protein,

wherein the peptide is linked to the N-terminus or C-terminus of the protein and the peptide facilitates or enhances the introduction of the protein or the nanoparticle into a cell.

2. A composition comprising:

a) a peptide comprising an amino acid sequence that is at least 80% identical to SEQ ID NO:1 (GSRVQIRCRFRNSTR), and

b) a protein selected from the group consisting of an alpha crystalline protein and small heat shock proteins HSPB1, HSPB2, HSPB3, HSPB4, HSPB5, HSPB6, HSPB7, HSPB8, HSPB9 and HSPB10;

wherein the peptide is linked to the protein and the peptide facilitates or enhances the introduction of the protein or the nanoparticle into a cell.

3. The composition of claim 2 , wherein the protein is selected from the group consisting of αA-crystallin and αB-crystallin.

4. The composition of claim 3 , wherein the peptide is linked to the N terminus of the protein.

5. The composition of claim 4 , wherein the composition comprises a sequence that is at least 90% identical to SEQ ID NO:2 or SEQ ID NO:4.

6. An isolated nucleic acid molecule comprising a nucleic acid sequence encoding the composition of claim 1 .

7. A recombinant nucleic acid molecule comprising the isolated nucleic acid molecule of claim 6 .

8. The composition of claim 1 wherein the composition further comprises a pharmaceutically acceptable carrier.

9. A method of treating a disease in an individual, comprising administering to the individual the composition of claim 1 and wherein the disease is selected form the group consisting of an ocular disease, neurodegenerative disease, myopathy, asthma, and cancer.

10. The method of claim 9 , wherein the ocular disease is selected from the group consisting of cataract, retinitis pigmentosa, retinopathy, age-related macular degeneration, uveitis, trauma and ischemia.

11. A method of treating a disease in an individual, comprising administering to the individual a composition comprising:

a) a peptide comprising an amino acid sequence that is at least 80% identical to SEQ ID NO:1 (GSRVQIRCRFRNSTR), and

b) a therapeutic protein or a heat shock protein or a crystallin protein,

wherein the peptide is linked to the N-terminus or C-terminus of the protein; the peptide facilitates or enhances the introduction of the protein into a cell, and wherein the protein provides a therapeutic benefit in the disease.

12. The composition of claim 2 , wherein the peptide is linked to the N-terminus or the C-terminus of the heat shock protein.

13. The composition of claim 2 , wherein the composition comprises a sequence that is at least 90% identical to SEQ ID NO:2 or SEQ ID NO:4.

14. The composition of claim 1 , wherein the composition comprises a sequence that is at least 90% identical to SEQ ID NO:2 or SEQ ID NO:4.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 15, 2013
From: PETRASH, JONATHAN MARK; MUELLER, NIKLAUS
To: THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE
Reel/Frame 031610/0306 →
CONFIRMATORY LICENSE Recorded Oct 31, 2013
From: UNIVERSITY OF COLORADO
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 031517/0806 →
Continuity (2)
Provisional Application 61469797 · Mar 30, 2011
Related Publication 20140235553A1 · Aug 21, 2014